New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2013
14:45 EDTINCYIncyte presents final results from a Phase I trial of INCB024360
Incyte presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 IDO1, inhibitor, INCB024360, at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies. Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:10 EDTINCYIncyte receives orphan status for pancreatic cancer treatment
Subscribe for More Information
January 23, 2015
07:36 EDTINCYIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use